Yuki Matsuda, Shinsuke Kito, Fumiyo Hiraki, Takuji Izuno, Katsuomi Yoshida, Motoaki Nakamura, Fumitoshi Kodaka, Ryuichi Yamazaki, Nanase Taruishi, Shinichi Imazu, Tetsufumi Kanazawa, Takahiro Mekata, Sotaro Moriyama, Masataka Wada, Shinichiro Nakajima, Kazuyuki Sawada, Shinya Watanabe, Shun Takahashi, Yuuki Toi, Daisuke Hayashi, Shun Igarashi, Ko Fujiyama, Shunichiro Ikeda, Hiroshi Tateishi, Ryohei Kojima, Kengo Sato, Shuken Boku, Minoru Takebayashi, Moritaka Ogura, Atsuhiko Takaya, Kenji Endo, Akira Kita, Hisatoshi Arai, Hisashi Kamimura, Koji Matsuo, Kenzo Denda, Sachi Yamashiro, Daisuke Yoshioka, Junichiro Kizaki, Masaru Mimura, Yoshihiro Noda
Psychiatry research 342 116263-116263 2024年11月10日
The objective of this study was to reveal the effectiveness of repetitive transcranial magnetic stimulation (rTMS) for Japanese patients with treatment-resistant depression (TRD) in clinical practice, based on real-world data from a nationwide multicenter observational study in Japan. Clinical data of patients with TRD treated with rTMS (NeuroStar TMS treatment system) under public insurance coverage were retrospectively collected from 21 institutes nationwide between June 2019 and December 2023. Depression severity was assessed by the 17-item Hamilton Depression Rating Scale (HAMD-17). Response and remission were defined as ≥50 % reduction from baseline and ≤7 points on the HAMD-17, respectively. The primary outcome was the changes in the HAMD-17 score from baseline to the endpoint following rTMS. Data from 497 patients with TRD were candidates for this study. The HAMD-17 scores (mean (SD)) improved significantly from 18.9 (5.3) to 9.7 (6.6), respectively. The response and remission rates at the end of rTMS therapy as assessed by the HAMD-17 were 53.5 % and 42.8 %, respectively. The dropout rate due to adverse effects was 4.2 %, and the treatment was generally well tolerated. No convulsive seizures or manic changes were observed. These results indicate that conventional rTMS is effective and safe in Japanese patients with TRD.